ScholarIQanswers from OpenAlex & ORCID
Martin J. van den Bent
ResearcherPublications, citations & collaboration network
Martin J. van den Bent is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Martin J. van den Bent have?
ScholarIQindexed works
Martin J. van den Bent has 1,349 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Martin J. van den Bent have?
ScholarIQcitation count
Martin J. van den Bent has 103,006 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Martin J. van den Bent?
ScholarIQh-index
Martin J. van den Bent has an h-index of 129 in OpenAlex.
What is the i10-index of Martin J. van den Bent?
ScholarIQi10-index
Martin J. van den Bent has an i10-index of 519 in OpenAlex.
What is the ORCID of Martin J. van den Bent?
ScholarIQorcid
The ORCID for Martin J. van den Bent is on the source record.
What is the OpenAlex record for Martin J. van den Bent?
ScholarIQopenalex
The OpenAlex for Martin J. van den Bent is on the source record.
What are the most-cited papers on Martin J. van den Bent?
ScholarIQmost cited works
Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial
Martin J. van den Bent, D Afra, Olivier De Witte, Mohamed Ben Hassel, S Schraub, Khê Hoang‐Xuan, P. Malmström, Laurence Collette, M. Piérart, René‐Olivier Mirimanoff, Abmf Karim
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma
Ingo K. Mellinghoff, Martin J. van den Bent, Deborah T. Blumenthal, Mehdi Touat, Katherine B. Peters, Jennifer Clarke, Joe Mendez, Shlomit Yust‐Katz, Liam Welsh, Warren Mason, François Ducray, Yoshie Umemura, Burt Nabors, Matthias Holdhoff, Andreas F. Hottinger, Yoshiki Arakawa, Juan Manuel Sepúlveda-Sánchez, Wolfgang Wick, Riccardo Soffietti, James Perry, Pierre Giglio, Macarena de la Fuente, Elizabeth A. Maher, Steven Schoenfeld, Dan Zhao, Shuchi S. Pandya, Lori Steelman, Islam Hassan, Patrick Y. Wen, Timothy F. Cloughesy
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
Martin J. van den Bent, Alba A. Brandes, R. Rampling, Mathilde C.M. Kouwenhoven, Johan M. Kros, Alain Carpentier, Paul M. Clément, M. Frénay, Mario Campone, Jean‐François Baurain, Jean-Paul Armand, Martin Taphoorn, Alicia Tosoni, Heidemarie Kletzl, Barbara Klughammer, Denis Lacombe, Thierry Gorlia
Transcriptome analysis reveals tumor microenvironment changes in glioblastoma
Youri Hoogstrate, Kaspar Draaisma, Santoesha A. Ghisai, Levi van Hijfte, Nastaran Barin, Iris de Heer, Wouter Coppieters, Thierry P. P. van den Bosch, Anne Bolleboom, Zhenyu Gao, Arnaud J.P.E. Vincent, Latifa Karim, Manon Deckers, Martin Taphoorn, Melissa Kerkhof, Astrid Weyerbrock, Marc Sanson, Ann Hoeben, Slávka Lukacova, Giuseppe Lombardi, Sieger Leenstra, Monique C.J. Hanse, Ruth Fleischeuer, Colin Watts, Nicos Angelopoulos, Thierry Gorlia, Vassilis Golfinopoulos, Vincent Bours, Martin J. van den Bent, Pierre A. Robe, Pim J. French
INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma
Martin J. van den Bent, Marica Eoli, Juan Manuel Sepúlveda-Sánchez, Marion Smits, Annemiek Walenkamp, Jean-Sebastian Frenel, Enrico Franceschi, Paul Clement, Olivier Chinot, Filip De Vos, Nicolas Whenham, Paul Sanghera, Michael Weller, H J Dubbink, Pim J. French, Jim Looman, Jyotirmoy Dey, Scott Krause, Pete Ansell, Sarah Nuyens, Maarten Spruyt, Joana Brilhante, Corneel Coens, Thierry Gorlia, Vassilis Golfinopoulos